{"id":24397,"date":"2024-07-12T16:01:48","date_gmt":"2024-07-12T14:01:48","guid":{"rendered":"https:\/\/mabdesign.fr\/?p=24397"},"modified":"2025-03-27T11:01:06","modified_gmt":"2025-03-27T10:01:06","slug":"glioblastoma","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/glioblastoma\/","title":{"rendered":"Glioblastoma"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MabDesign’s market analyses give you a monthly overview of market dynamics and projects<\/span> in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, an overview of the market and projects currently under development for the treatment of glioblastoma.<\/span><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Glioblastoma Multiform (GBM)<\/em><\/span> accounts for 15% of all brain tumors<\/strong>, and is also the most aggressive form. It represents a major public health challenge on a global scale. With an estimated annual incidence of 2 to 3 cases per 100,000<\/strong> inhabitants, it affects around 250,000 people worldwide every year. Its prognosis remains poor, with a median survival of just 15 months after diagnosis.<\/p>\n

Its biological complexity and resistance to conventional treatments<\/strong> make glioblastoma a real therapeutic nightmare. Research is intensifying to decipher the underlying mechanisms of the pathology, and develop new, more effective therapeutic approaches. This is illustrated by the growing number of biotherapies in development targeting this indication. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Epidemiological data<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

2-3<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

cases per 100,000 inhabitants <\/strong>in Europe and North America<\/em><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

14,6<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

months median survival<\/strong><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

14,5 %<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

of all brain tumors<\/strong><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Glioblastoma Market<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The global glioblastoma market is currently estimated at $3 billion. It should continue to grow <\/b>, with a CAGR of between 3% and 10% over the coming years. As in the global drug market, the glioblastoma market is dominated by small molecules, with only 22% of available products being biologics. <\/strong> <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Market<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
US$ billions<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

3-10%<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

CAGR<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Molecule type<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t
<\/h5><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
2023 Dynamics<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
deals<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
new biologics in the pipeline<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Pipeline of projects targeting Glioblastoma<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In terms of molecule types, the ratio is reversed in the pipeline, with a<\/span> preponderance of biomedicines (64%) <\/b><\/span>. The pipeline of biomedicines targeting glioblastoma is rich, with some 400 molecules in development, and also very varied, with many different therapeutic approaches, and notably many MTIs <\/a> (41.9%)<\/strong>. There are also numerous antibody projects (25.6%). <\/span><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Pipeline<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t
<\/h5><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
biologics in the pipeline<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Types of biologics<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t
<\/h5><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Download our infographic<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Gliobastoma market<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"march\u00e9\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
<\/path><\/svg><\/span>Download in .pdf format<\/span><\/span><\/small><\/span><\/a>\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Want to find out more? <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MabDesign has acquired and cultivates its expertise in all market segments associated with biopharmaceuticals and biomanufacturing. Our team<\/a> of consultants is at your disposal to support you in all your biotherapy-related projects. Feel free to explore our range of services<\/a>, including our marketing and strategic analyses<\/a>, if you’d like to find out more!<\/i><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tContact us<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sources: MabDesign & GlobalData<\/p>\n

Date – July 2024<\/span><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

This month’s MabDesign market analysis gives you an overview of market dynamics and pipeline projects targeting the glioblastoma.<\/p>\n","protected":false},"author":4,"featured_media":24333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[83,88,119],"tags":[121,257,158,98,141,160,157,259,159,255,256],"class_list":["post-24397","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analyses-marche","category-bio-hub-en","category-market-analysis-en","tag-cancer-en","tag-cell-and-gene-therapy","tag-glioblastoma","tag-innovation-en","tag-market","tag-neurology","tag-oncology-en","tag-other-biologics","tag-pipeline-analysis-en","tag-therapeutic-antibodies-and-proteins","tag-vaccines-en"],"yoast_head":"\nMarket Glioblastoma - MabDesign<\/title>\n<meta name=\"description\" content=\"The MabDesign market analysis gives you an overview of the market and projects currently in development targeting glioblastoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/glioblastoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Market Glioblastoma - MabDesign\" \/>\n<meta property=\"og:description\" content=\"The MabDesign market analysis gives you an overview of the market and projects currently in development targeting glioblastoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/glioblastoma\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-12T14:01:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-27T10:01:06+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/07\/Glioblastoma-July.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"2000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anabelle Perrier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anabelle Perrier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/\"},\"author\":{\"name\":\"Anabelle Perrier\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918\"},\"headline\":\"Glioblastoma\",\"datePublished\":\"2024-07-12T14:01:48+00:00\",\"dateModified\":\"2025-03-27T10:01:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/\"},\"wordCount\":375,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/07\/Glioblastoma-July.png\",\"keywords\":[\"cancer\",\"Cell and Gene therapy\",\"glioblastoma\",\"innovation\",\"market\",\"neurology\",\"oncology\",\"Other Biologics\",\"pipeline analysis\",\"Therapeutic antibodies and proteins\",\"Vaccines\"],\"articleSection\":[\"Analyses march\u00e9\",\"Bio-hub\",\"Market analysis\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/\",\"name\":\"Market Glioblastoma - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/07\/Glioblastoma-July.png\",\"datePublished\":\"2024-07-12T14:01:48+00:00\",\"dateModified\":\"2025-03-27T10:01:06+00:00\",\"description\":\"The MabDesign market analysis gives you an overview of the market and projects currently in development targeting glioblastoma.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/glioblastoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/07\/Glioblastoma-July.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/07\/Glioblastoma-July.png\",\"width\":1500,\"height\":2000,\"caption\":\"march\u00e9 glioblastome\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/glioblastoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glioblastoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918\",\"name\":\"Anabelle Perrier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g\",\"caption\":\"Anabelle Perrier\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/anabelle-perriermabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Market Glioblastoma - MabDesign","description":"The MabDesign market analysis gives you an overview of the market and projects currently in development targeting glioblastoma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/glioblastoma\/","og_locale":"en_US","og_type":"article","og_title":"Market Glioblastoma - MabDesign","og_description":"The MabDesign market analysis gives you an overview of the market and projects currently in development targeting glioblastoma.","og_url":"https:\/\/mabdesign.fr\/en\/glioblastoma\/","og_site_name":"MabDesign","article_published_time":"2024-07-12T14:01:48+00:00","article_modified_time":"2025-03-27T10:01:06+00:00","og_image":[{"width":1500,"height":2000,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/07\/Glioblastoma-July.png","type":"image\/png"}],"author":"Anabelle Perrier","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Anabelle Perrier","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/glioblastoma\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/glioblastoma\/"},"author":{"name":"Anabelle Perrier","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918"},"headline":"Glioblastoma","datePublished":"2024-07-12T14:01:48+00:00","dateModified":"2025-03-27T10:01:06+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/glioblastoma\/"},"wordCount":375,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/glioblastoma\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/07\/Glioblastoma-July.png","keywords":["cancer","Cell and Gene therapy","glioblastoma","innovation","market","neurology","oncology","Other Biologics","pipeline analysis","Therapeutic antibodies and proteins","Vaccines"],"articleSection":["Analyses march\u00e9","Bio-hub","Market analysis"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/glioblastoma\/","url":"https:\/\/mabdesign.fr\/en\/glioblastoma\/","name":"Market Glioblastoma - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/glioblastoma\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/glioblastoma\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/07\/Glioblastoma-July.png","datePublished":"2024-07-12T14:01:48+00:00","dateModified":"2025-03-27T10:01:06+00:00","description":"The MabDesign market analysis gives you an overview of the market and projects currently in development targeting glioblastoma.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/glioblastoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/glioblastoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/glioblastoma\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/07\/Glioblastoma-July.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/07\/Glioblastoma-July.png","width":1500,"height":2000,"caption":"march\u00e9 glioblastome"},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/glioblastoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Glioblastoma"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918","name":"Anabelle Perrier","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g","caption":"Anabelle Perrier"},"url":"https:\/\/mabdesign.fr\/en\/author\/anabelle-perriermabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/24397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=24397"}],"version-history":[{"count":15,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/24397\/revisions"}],"predecessor-version":[{"id":24717,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/24397\/revisions\/24717"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/24333"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=24397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=24397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=24397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}